Two novel bifunctional chelates, 3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3,6,9-triacetic acid (PCTA) and 1-oxa-4,7,10-triazacyclododecane-4,7,10-triacetic acid (Oxo-DO3A), were found to radiolabel antibodies with copper 64 ( 64 Cu) well for positron emission tomography (PET). In this study, the same chelators were used to radiolabel peptides with 64 Cu for PET imaging of angiogenesis. PCTA, Oxo-DO3A, and 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA) were conjugated to cyclic-(RGDyK), and their binding affinities were confirmed. Conditions for 64 Cu radiolabeling were optimized for maximum yield and specific activity. The in vitro stability of the radiolabeled compounds was challenged with serum incubation. PET studies were carried out in a non-a v b 3 -expressing tumor model to evaluate the compounds' specificity for proliferating tumor vasculature and their in vivo pharmacokinetics. The PCTA and Oxo-DO3A bioconjugates were labeled with 64 Cu at higher effective specific activity and radiochemical yield than the DOTA bioconjugate. In the imaging studies, all the 64 Cu bioconjugates could be used to visualize the tumor and the radiotracer uptake was blocked with cyclic-(RGDyK). Target uptake of each bioconjugate was similar, but differences in other tissues were observed. 64 Cu-PCTA-RGD showed the best clearance from nontarget tissue and the highest tumor to nontarget ratios. PCTA was the most promising bifunctional chelate for 64 Cu peptide imaging and warrants further investigation.
C OPPER 64 ( 64 Cu) is a radioisotope that has generated much interest for use in nuclear medicine due to its favorable nuclear and chemical properties. The emissions of 64 Cu are suitable for positron emission tomography (PET) and potentially for targeted radiotherapy. The 12.7hour half-life also makes this Cu isotope useful for imaging with numerous targeting vectors with a large range of biologic half-lives, from small peptides to antibodies.
Bifunctional chelates (BFCs) are typically used for simple and efficient radiolabeling of targeting vectors with 64 Cu by taking advantage of the metal's coordination chemistry. The ideal BFC facilitates radiolabeling reactions with high radiochemical yields and effective specific activities in short reaction times under mild aqueous conditions. The resulting complex must retain affinity for the target and not be susceptible to loss of the radioisotope from the complex whether through degradation or exchange reactions in vivo. In addition, the physical properties of the BFC, such as size, charge, and lipophilicity, can modulate the uptake and clearance of the labeled compound from target and nontarget tissue. [1] [2] [3] [4] Numerous BFCs have been evaluated with 64 Cu. 1,3-8 Many of the peptide imaging studies with 64 Cu have used 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA), [9] [10] [11] but DOTA does not always retain the isotope in vivo. 4, 12 Slightly better stability has been noted for the larger macrocycle triethylenetetramine (TETA), although transchelation of 64 Cu from TETA into superoxide dismutase (SOD) has been reported. But this may not have a significant impact on radiolabeled peptide imaging because images are acquired relatively soon after injection. 12, 13 Labeling with another chelate, 4,11-bis(carboxymethyl)-1,4,8,11-tetraaza bicyclo[6.6.2]hexadecane (CB-TE2A), significantly improved in vivo stability, resulting in better nontarget tissue clearance. 4, 14 Unfortunately, harsh radiolabeling conditions are required with CB-TE2A, which limits its use to targeting vectors that remain stable under these conditions. 1 Numerous studies have been done using CB-TE2A to attach 64 Cu to peptides that are impervious to the prolonged heat exposure necessary for radiolabeling of this chelate. 4, [14] [15] [16] Comparisons with other chelate systems have confirmed the improved imaging properties when using CB-TE2A. 4,14,17 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) has been used for radiolabeling peptides with 64 Cu, but in some cases, it has also been reported to require prolonged heating. 18, 19 Finally, the 1-N-(4-aminobenzyl)-3,6,10,13,16,19-hexaazabicyclo[6.6.6]eicosane-1,8-diamine (SarAr) system has been studied with 64 Cu and has been reported to chelate Cu with high efficiency under mild conditions, forming a very stable complex. Comparative studies between SarAr and other chelates have shown SarAr to have good nontarget clearance and, in some cases, significantly higher tumor uptake, 20,21 but higher kidney uptake has also been observed, possibly due to the +2 charge of the complex. 22 Two novel BFCs, 3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3,6,9-triacetic acid (PCTA) and 1-oxa-4,7,10-triazacyclododecane-4,7,10-triacetic acid (Oxo-DO3A), have been studied by our group for radiolabeling biomolecules with 64 Cu. 6 These chelates have ideal properties with respect to radiolabeling and stability. High radiochemical yields were achieved under mild conditions in ,10 minutes, and the complexes were shown to be stable in vitro. Our group has also shown that these chelates could be used to label antibodies with 64 Cu for imaging HER2-positive breast tumors, 23 but the impact of the chelates on tracer pharmacokinetics was not observed as the antibody dominated the biodistribution of the complex.
The goal of this present study was to further probe the use of PCTA and Oxo-DO3A ( Figure 1 ) with small targeting peptides and 64 Cu for PET imaging. The small peptide cyclic-(RGDyK) was used because it has been extensively studied and validated as a useful targeting vector for PET imaging. 14, 24 We also felt that the small size of the peptide (MW 621 g/mol) would better allow us to explore the impact of the chelate structures on the pharmacokinetics of the radiotracer. RGD peptides are known to target the a v b 3 receptor, which is expressed on some tumors and on endothelial cells of the tumor neovasculature. 25 There is interest in imaging a v b 3 expression noninvasively to select patients for antiangiogenic therapies and monitoring treatment response. 26 Thus, as part of this study, our group wanted to examine the utility of these 64 Cuchelated peptides for imaging tumor angiogenesis in situ. The imaging studies were thus carried out in a tumor model (HT-29), where the cancer cells have a low a v b 3 expression level 27 but whose neovasculature has a high density of a v b 3 -positive endothelial cells in the tumor ( Figure 2 ).
PCTA, Oxo-DO3A, and DOTA were conjugated to the small peptide cyclic-(RGDyK), and the binding affinities of the bioconjugates were determined. The bioconjugates were subsequently radiolabeled with 64 Cu, and the in vitro stability of the resulting complexes was compared. Finally, imaging and biodistribution studies were carried out in mice bearing HT-29 tumors with each of the labeled RGDchelator complexes to examine the impact of the chelate on the tracer pharmacokinetics and their utility for imaging tumor neovasculature.
Experimental Details

Materials and Methods
All solvents and reagents were used as received unless otherwise noted. The BFCs p-SCN-Bn-DOTA, p-SCN-Bn-Oxo-DO3A, and p-SCN-Bn-PCTA were acquired from Macrocyclics Inc. (Dallas, TX). 125 I-echistatin was purchased from PerkinElmer (Boston, MA). 64 Cu was obtained as dilute HCl solutions (Nordion, Vancouver, BC). Cyclic-(RGDyK) was purchased from either Anaspec (Fremont, CA) or Peptides International (Louisville, KY). Water was deionized using a Milli-Q biocel A-10 water purification system. Reaction vials were acid washed to remove impurities and trace metals. After being soaked in concentrated acid (HNO 3 ), the vials were rinsed thoroughly with purified water and then dried at 200uC for 2 hours.
The high-performance liquid chromatography (HPLC) system used for analysis consists of a Waters Alliance HT 2795 separation module equipped with a Raytest Gabi star NaI detector and a Waters 996 photodiode array detector. Analysis of radiolabeled complexes was done on a Waters XBridge BEH130 RPC18 4.6 3 150 mm analytic column using a binary solvent system; solvent A 5 acetonitrile, solvent B 5 0.05% trifluoroacetic acid in water, gradient elution 5%A 95%B to 100%A over 30 minutes at 1 mL/min. Positive identification of the radiolabeled bioconjugates was made by comparison of the retention time of the radiodetector peak and the ultraviolet detector peak associated with the macroscopic scale complex of the respective bioconjugate, whose identity was verified by mass spectroscopy using positive-ion mode electrospray ionization with a Micromass Q-TOF Ultima API time-of-flight mass spectrometer by Mr. Andras Szeitz (Department of Pharmaceutical Sciences, University of British Columbia). Analysis of the stability samples was done by HPLC using the method described above or using size exclusion PD-10 columns (GE) eluting with phosphate-buffered saline (PBS) (pH 7.2).
Conjugation Chemistry
Each of the three BFCs was conjugated to the cyclic-(RGDyK) (see Figure 1 ). Briefly, the BFC was dissolved in 50 mM HEPES buffer at pH 9 and the peptide was added to the freshly made solution. HPLC ([Waters, Elstree Hertfordshire, UK] XBridge BEH130 RPC18 4.6 3 150 mm analytic column gradient elution 5%A 95%B to 100%A over 30 minutes at 1 mL/min; solvent A 5 acetonitrile, solvent B 5 0.05% trifluoroacetic acid in water) was used to monitor the progress of the reaction and to purify the formed conjugates. Purification of the conjugates was done using the analytic column and gradient described in the Materials and Methods section but with ethanol and deionized water as the 
Radiochemistry and Stability
To 1 mL 10 mM sodium acetate buffer pH 5 solution containing 20 to 100 nmol of bioconjugates, 20 to 100 MBq (10-50 mL) of 64 Cu in 0.01 N HCl was added. The reaction was incubated at room temperature for 10 minutes and analyzed by HPLC to determine the radiochemical yield and purity of the labeled bioconjugate.
To evaluate the stability of the radiolabeled complexes, 15 MBq of each of the 64 Cu radiolabeled bioconjugates was incubated in mouse serum (400 mL) at 37uC. After 24 hours of incubation, the samples were analyzed by HPLC to determine if any of the 64 Cu was lost to serum proteins.
Cell Lines
U87MG human glioblastoma cells were maintained in medium (Dulbecco's Modified Eagle's Medium supplemented with 2 mM L-glutamine, Invitrogen, Vancouver, BC) and 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA) under 95% air and 5% CO 2 at 37uC. Prior to use, the cells were washed twice with PBS, harvested (by incubation with 2 mL of 0.25% trypsin/ ethylenediaminetetraacetic acid [EDTA] for 1 minute at 37uC, with subsequent addition of 4 mL medium), and resuspended (1 3 10 6 cells/mL) in binding buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 2 mM CaCl 2 , 1 mM MgCl 2 , 1 mM MnCl 2 , 0.1% bovine serum albumin [BSA]).
HT-29 human colon adenocarcinoma cells were obtained from ATCC (Manassas, VA) and were certified Mycoplasma negative. Cells were cultured in McCoy's 5A (StemCell Technologies, Vancouver, CA), supplemented with 1% L-glutamine, 1% penicillin/streptomycin, and 10% FBS. Plated flasks were kept in a humidified incubator (5% CO 2 , 37uC) and passaged when < 80 to 90% confluence. Medium was renewed at least once weekly. Tissue culture flasks, tubes, and plates (BD Falcon) were obtained from BD Sciences (Bedford, MA). Prior to use, cells were detached from the surface of the tissue culture flask by treatment with 0.25% trypsin/EDTA (Sigma, St. Louis, MO).
In Vitro Studies
The binding affinity of each of the unlabeled bioconjugates was confirmed using a v b 3 -positive U87MG glioblastoma cells as described previously. 28 Briefly, filter plates (multiscreen DV [polyvinylidene fluoride] plates, 96 wells, 0.65 mm pore size, Millipore, [B.V.], Carrigtwohill, County Cork, Ireland) were seeded with 10 5 cells per well and incubated with 125 I-echistatin (20,000 cpm) along with increasing concentrations (0-2 mM) of one of the bioconjugates. After incubating for 2 hours, unbound 125 I-echistatin was removed with several washes, the filters were collected, and the activity was measured (gamma counter, Cobra-II Auto Gamma, Canberra Packard Canada) to determine the amount of bound 125 I-echistatin.
In Vivo Studies
Animal studies were conducted with the full approval of the University of British Columbia's Animal Care Committee, operating under the auspices of the Canadian Animal Care Committee. HT29 tumors were grown subcutaneously on Rag2M (disrupted recombination activating gene) mice as reported previously 29 ; briefly, 5 3 10 6 cells (50 mL) were injected subcutaneously on the lower back of Rag2M mice. Once tumors reached < 100 to 150 mm 3 , mice were anesthetized with isoflurane (5% induction, 3% maintenance) and injected intravenously with the 64 Cu-radiolabeled cyclic-(RGDyK) conjugated to DOTA, PCTA, or Oxo-DO3A (< 5.5 MBq, 1.6 GBq/mmol). Groups (n 5 5) of mice were injected with one of the three radiolabeled bioconjugates, Cu-64-DOTA-, -Oxo-DO3A-, or -PCTA-cyclic-(RGDyK), and were imaged for 2 hours postinjection. Imaging was carried out in the Siemens Inveon multimodality computed tomography (CT)-PET small-animal scanner. 30 Images were reconstructed in three dimensions using ordered-subsets expectation maximization maximum a posterior 3-dimensions (OSEM-MAP3D) algorithms supplied by Siemens following CT-based attenuation scans to correct for the animal's body mass.
Once imaged, mice were euthanized. The blood, liver, kidney, muscle, and tumor tissue were harvested, weighed, and placed in a scintillation counter to determine the activity present per gram of tissue. Three-dimensional regions of interest (ROI) were placed on the heart (to approximate the activity present in the blood), kidney, liver, muscle (lower leg), and tumor in reconstructed images of the imaged mice. Only ROI greater than 75 mm 3 were used in the analysis to minimize partial volume effects. The activity present in each ROI was determined in becquerels per milliliter based on a calibration scan done with a phantom of known activity to determine camera efficiency and sensitivity.
Tumors from a parallel group of mice that did not undergo scans were preserved in optimum cutting temperature (OCT, Sakura Finetek, Torrance, CA) and snap-frozen in liquid nitrogen vapor. Ten-micrometer cryosections were cut for each tumor and air-dried. The cryosections were fixed in ice-cold acetone for 15 minutes and blocked for 20 minutes at room temperature in a buffer containing 1% BSA, 1% goat serum, 1% donkey serum, and 0.1% Tween 20. For vitronectin receptor (a V b 3 ) immunohistochemistry staining on human cancer cells, slides were treated for 20 minutes with H 2 O 2 before staining overnight with mouse antihuman a V b 3 (Millipore) at 4uC. Positive staining was detected by antimouse-horseradish peroxidase (Promega) secondary antibodies and NovaRed peroxidase reagent (Vector Labs) before counterstaining with hematoxylin. For b3 (CD61) immunofluorescence detection of the integrin on mouse-derived tumor vasculature, slides were stained overnight with hamster antimouse-CD61 antibodies (BD Pharmingen) at 4uC, followed by goat antihamster-fluorescein isothiocyanate (Jackson ImmunoResearch) secondary antibodies. b3 slides were double-stained with biotin-rat anti-CD31 (BD Pharmingen) primary antibodies to visualize endothelial cells and detected with streptavidin-Alexa 647 (Molecular Probes) secondary antibodies at room temperature before counterstaining with Hoechst 33362 (Sigma). Tumor section images were captured (310 objective) using a Leica microscopic imaging system (Leica Microsystems Inc., Richmond Hill, ON) equipped with a cooled 350FX monochrome charge-coupled device camera, an automated scanning stage (DM6000B), and Surveyor software (Objective Imaging, Kansasville, WI).
Statistical Analysis
Data from the animal studies for each of the radiolabeled conjugates, both the blocked and nonblocked groups, were compared using statistical analysis, specifically unpaired two-tailed t-tests; p values # .05 were considered statistically significant.
Results and Discussion
Chemistry Each BFC was conjugated to cyclic-(RGDyK) peptide (see Figure 1) , with high yields of < 80% after HPLC purification. The conjugates formed within 2 to 3 hours (40-60% yield), but optimal yields were obtained when the reaction was left overnight. One advantage to this conjugation reaction is the atom economy; near-stoichiometric amounts of chelate and peptide can be conjugated with minimal side products. In comparison, the commonly used method of forming an amide via an activated ester often requires an excess of chelate (up to 50 equivalents) to facilitate conjugation. 9, 18, 22, 31 As the activated ester is often prepared in situ, numerous impurities and byproducts, along with the excess unreacted chelate, must be removed from the final conjugate. For the isothiocyanate conjugation method, only a small excess of chelate (10%) is required and only small amounts of unreacted chelate, peptide, and buffer salts need removal.
The thiourea linkage was found to be stable toward hydrolysis. Aqueous solutions of the bioconjugates that had been kept refrigerated were analyzed by HPLC during radiolabeling experiments, and no apparent degradation of the conjugates was observed within 3 months of the initial synthesis.
Each bioconjugate retained its affinity for the a v b 3 integrin. Competitive inhibition of 125 I-echistatin by each conjugate was compared to the nonconjugated peptide using the a v b 3 -expressing U87MG glioma cells. Each bioconjugate was found to inhibit 125 I-echistatin in a dose-dependent manner with the following half-maximal inhibitory concentration values (mM/L): cyclic-RGD (0.4 6 0.1); PCTA-RGD (1.8 6 0.6); Oxo-DO3A-RGD (0.6 6 0.2), and DOTA-RGD (2.7 6 0.3).
Radiochemistry
All of the conjugates could be efficiently radiolabeled in 95% radiochemical yield with 64 Cu at room temperature within 10 minutes. However, when lower concentrations of bioconjugate were used to facilitate higher effective specific activity radiolabeling, differences in the chelates were observed. When the radiolabeling was carried out at bioconjugate concentrations of 25 mM, PCTA-RGD, Oxo-DO3A-RGD, and DOTA-RGD were labeled in 10 minutes with 99.9 6 0.1, 99.9 6 0.1, and 98.9 6 0.2% radiochemical yield with specific activities of 7.4 6 0.1, 7.4 6 0.1, and 7.3 6 0.2 GBq/mmol, respectively. When bioconjugate concentrations of 10 mM were used, PCTA and Oxo-DO3A were labeled within 10 minutes with percent radiochemical yields of 98.9 6 0.1 and 95.7 6 0.8, respectively, but threefold greater specific activity (23 6 0.1 and 21 6 0.3 GBq/mmol, respectively). In contrast, the percent radiochemical yield for DOTA-RGD was 89 6 3 after 60 minutes with a specific activity of 20 6 1 GBq/mmol. DOTA-RGD did not radiolabel as well as PCTA-and Oxo-DO3A-RGD and required longer reaction times but with lower percent radiochemical yields. High radiochemical yields in short reactions times at room temperature are advantageous for simple kit-type preparations in a radiopharmacy, where HPLC purification may not be possible. The ability to radiolabel at 37uC or lower can be necessary to maintain the integrity of the targeting vector (in some cases). Thus, PCTA and Oxo-DO3A may be better chelates than DOTA for 64 Cu radiolabeling of small peptides because of their shorter reaction time, especially at lower concentrations, and mild reaction conditions.
In vitro stability was assessed by incubating the 64 Curadiolabeled bioconjugates in a 50/50 solution of mouse serum and saline. Negligible loss of isotope to serum protein was observed up to the 4-hour time point. At 24 hours, a small amount (< 5%) of 64 Cu was lost from the radiolabeled DOTA-RGD conjugate and associated with serum proteins. It has been noted that 64 Cu-radiolabeled DOTA is prone to transmetallation of the Cu to other proteins, 12 but the small amount of serum protein association noted at 24 hours is unlikely to have a significant effect on the utility of the DOTA-RGD analogue because small RGD peptide conjugates clear rapidly from the blood and optimal imaging times are between 1 and 4 hours. 4, 9, 14, 22 However, evaluation of stability through in vivo biodistribution can be more informative with respect to other tissues that 64 Cu is known to be sequestered in, such as the liver.
Animal Studies
Our group was primarily interested in the potential utility of these bioconjugates for imaging angiogenesis in vivo. Thus, we chose to carry out the biodistribution and imaging studies in HT-29 tumors, which do not express the a v b 3 integrin on the cells' surface but are highly vascular and have high levels of angiogenic activity. Immunohistochemical staining using antibodies specific for human a v and murine b 3 portions of the integrin was carried out to determine the distribution of the a v b 3 integrin in HT-29 tumors (see Figure 2 ). U87MG tumors, which are known to express the a v b 3 integrin on their cells, were used as a positive control (see Figure 2A) ; positive staining for the integrin (brown) was readily observed around cell nuclei (blue), as expected. In contrast, positive staining for a v was negligible in HT-29 tumors (see Figure 2B ). Endothelial cells and murine b 3 present on the tumor vasculature were stained with CD31 (red) and CD61 (green), respectively. The merged images (see Figure 2C) show that a v b 3 integrin expression is present only on mouse vasculature. Thus, in the imaging experiments, the signal from the tumors is due to binding of the bioconjugates to the tumor vasculature.
The clearance and imaging characteristics of the 64 Curadiolabeled bioconjugates can be seen in Figure 3 and Figure 4 . In all cases, the tracer cleared from blood and muscle quickly, with the most activity found in the kidney, liver, and tumor tissues. Despite the lack of a v b 3 integrin expression on the tumor cells, the tumor uptake was significantly higher than the nontarget tissue uptake 2 hours postinjection (eg, blood and muscle). The tumor uptake was also significantly reduced (p , .05) from 2.0 6 0.4, 2.8 6 0.4, and 2.9 6 0.6 to 1.1 6 0.3, 2.2 6 0.3, and 1.5 6 0.4 for 64 Cu-radiolabeled PCTA-RGD, Oxo-DO3A-RGD, and DOTA-RGD, respectively, when the mice were injected simultaneously with the 64 Cu bioconjugate and excess peptide cyclic-(RGDyK), further suggesting that the binding of the 64 Cu-radiolabeled RGD conjugates is to growing mouse endothelial vascular cells within the tumor. No difference in nontarget tissue uptake was observed between the blocked and nonblocked animals. Optimal images, when the tumor to nontarget ratios were highest, were observed around 60 minutes postinjection. Although the %ID/g values determined by biodistribution at 2 hours (Table 1) were larger than the %ID/g values determined from ROI analysis of the images at 110 minutes, the values correlated well; the Pearson correlation coefficient was . 0.9 for each of the 64 Curadiolabeled bioconjugates.
Several differences between the chelates were observed in imaging and biodistribution experiments. Most notably, significantly higher nontarget tissue uptake, especially in the liver, was observed for 64 Cu-radiolabeled Oxo-DO3A-RGD species. Free 64 Cu that has not been cleared has been shown to localize in the liver, 7, 23 suggesting that 64 Curadiolabeled Oxo-DO3A-RGD may be susceptible to the loss of Cu in vivo despite the stability challenge results with mouse serum. A previous study with 64 Cu-radiolabeled Oxo-DO3A conjugate of bombesin also indicated in vivo instability despite high stability indicated by an in vitro serum challenge. 32 Although mammal serum contains SOD, which has been implicated in the liver retention of Cu, the concentration, stability, or activity of the enzyme in frozen mouse serum may not be adequate to assess the biologic stability of Cu-radiolabeled agents. 64 Cu-PCTA-RGD and 64 Cu-DOTA-RGD produced similar imaging results, but the PCTA bioconjugate had better clearance from nontarget tissue. For instance, the average tumor to muscle ratio for 64 Cu-PCTA-RGD was found to be significantly (p , .05) higher than for 64 Cu-DOTA-RGD from the 2-hour biodistribution measurements, 5.1 compared to 2.4, respectively ( Figure 5) . Notably, the average tumor to muscle ratio for 64 Cu-DOTA-RGD was similar for both the blocked and nonblocked mice due to the poor clearance of 64 Cu-DOTA-RGD from nontarget tissue. Faster clearance of 64 Cu-radiolabeled PCTA compared to DOTA from blood, muscle, and liver has been noted previously, but the clearance differences were less pronounced with the conjugation of a biomolecule, even a small peptide as seen here.
Conclusions
Oxo-DO3A, PCTA, and DOTA were compared for their efficacy in 64 Cu radiolabeling and value for facilitating PET imaging with small peptides. Each of the three BFCs was shown to be easily conjugated to the small peptide cyclic-(RGDyK). The resulting bioconjugates could be efficiently labeled with 64 Cu and used to specifically image a v a 3 expression in angiogenic endothelial cells in HT-29 tumors. PCTA-RGD was more efficiently radiolabeled than DOTA-RGD, and 64 Cu-radiolabeled PCTA-RGD had the best nontarget tissue clearance and tumor to nontarget ratios. Despite the stability indicated by in vitro measurements, 64 Cu-radiolabeled Oxo-DO3A-RGD had high liver retention, suggesting poor in vivo stability; Oxo-DO3A may not be the ideal chelate for 64 Cu radiolabeling and imaging of small peptides. The results of this study show that PCTA is a promising chelate for peptide imaging. Further studies using PCTA for 64 Cu radiolabeling of peptides and small proteins are warranted, including comparison of PCTA with other BFCs that have been shown to be advantageous for 64 Cu radiolabeling, such as CB-TE2A. 
